Saturday 17 October 2026
Export IRLA’s income statement to Excel — free account
Quince Therapeutics, Inc.
IRLA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 81.9%, free cash flow fell 63.7% and total debt rose 28.2%, each against the same quarter a year earlier.
32.17
1.06
−3.19%
Follow IRLA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | 3,870.00 | 5,332.20 | 2,142.00 | 108.00 | 127.40 | 102.40 | 144.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | 14,588.00 | 14,768.00 | 24,396.00 | 2,740.00 | 386.00 | 490.00 | 910.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 16 | 23 | 37 | 55 | 21 | 32 | 36 | 38 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | (12) | (12) | (37) | (77) | (90) | (52) | (32) | (57) | (81) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | (12) | (12) | (37) | (77) | (90) | (52) | (31) | (57) | (84) | |||||
| Depreciation | — | 0 | 0 | (1) | 1 | 1 | 1 | 4 | 15 | (1) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | (740.84) | (742.13) | (388.00) | (526.00) | (606.00) | (308.00) | (168.00) | (262.00) | (336.00) | |||||
| Cash flow | — | (595.58) | (696.13) | (349.55) | (348.31) | (423.50) | (262.91) | (98.24) | (147.50) | (165.37) | |||||
| Capex | — | (4.67) | (12.62) | (0.58) | (0.36) | (1.21) | (0.38) | (0.38) | (1.19) | (1.41) | |||||
| Free cash flow | — | (600.24) | (708.75) | (350.13) | (348.66) | (424.71) | (263.29) | (98.61) | (148.69) | (166.77) | |||||
| Book value | — | (1,229.09) | (1,942.02) | 1,213.00 | 1,180.69 | 798.02 | 600.56 | 456.95 | 139.37 | (142.57) | |||||
| Shares, m | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | (10) | (12) | (33) | (51) | (63) | (44) | (18) | (32) | (41) | ||||
| Capex | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | (10) | (12) | (33) | (51) | (63) | (44) | (18) | (32) | (42) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 6 | 71 | 97 | 121 | 97 | 91 | 68 | 37 | (20) | ||||
| Total debt | — | 7 | — | — | 0 | 1 | 0 | 13 | 14 | 18 | |||||
| Net debt | — | 0 | (72) | (100) | (133) | (106) | (90) | (62) | (26) | 0 | |||||
| Shareholders’ equity | — | (20) | (33) | 115 | 172 | 119 | 101 | 85 | 30 | (36) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (30.36) | (30.96) | (37.50) | (48.97) | (55.75) | (43.57) | (23.09) | (40.25) | (80.75) | ||||
| ROIC | — | 0.00 | 0.00 | (156.78) | (126.80) | (436.07) | (299.21) | (92.26) | (972.12) | 0.00 | |||||
| ROE | — | 46.25 | 47.16 | (89.27) | (53.42) | (61.85) | (47.14) | (33.81) | (98.63) | 3,016.49 | |||||
Negative figures in brackets.
Charts ten years each
Quince Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NNVC NanoViricides, Inc. | $35.0M | — (loss-making) | — | — | n/m | −23.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CRVO CervoMed Inc. | $34.0M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −6.20% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IRLA Quince Therapeutics, Inc. | $33.8M | — (loss-making) | — | — | n/m | −63.65% (below 0%: shrinking) | 0.00% | 0.00% | |
| ALGS Aligos Therapeutics, Inc. | $33.7M | — (loss-making) | — (loss-making) | +2,778.55% (above 0%: growing) | n/m | −59.81% (below 0%: shrinking) | 100.00% | (6.80%) | Compare |
| ATNM Actinium Pharmaceuticals, Inc. | $33.3M | 3.1× | — (loss-making) | +77,677.78% (above 0%: growing) | n/m | −4.91% (below 0%: shrinking) | 100.00% | 78.76% | Compare |
| BCTX BRIACELL THERAP | $32.8M | 1.5× | — | — | n/m | +0.21% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GNTA Genenta Science S.p.A. Unsponsored ADR | $32.3M | — | — | — | — | +35.94% (above 0%: growing) | 0.00% | — | Compare |
| MGX Metagenomi Therapeutics, Inc. | $31.9M | — (loss-making) | — (loss-making) | −103.02% (below 0%: shrinking) | n/m | +7.98% (above 0%: growing) | 100.00% | 11,195.72% | Compare |
| Median of peers | $33.5M | 1.5× | — | +1,339.48% | — | −2.35% | 50.00% | 0.00% |
Quince Therapeutics, Inc. (IRLA) key facts
- Quince Therapeutics, Inc. (IRLA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, IRLA traded at $32.17, a market capitalization of $33.8 million.
- Return on equity was 3,016.5% and debt-to-equity 0.00.